PACTG 382: DMP 266 & NELFINAVIR COMBINATION IN HIV-INFECTED CHILDREN (AIDS)

PACTG 382：DMP 266

• 批准号: 7378249
• 负责人: William Borkowsky
• 金额: $ 0.5万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7378249
• 关键词: PACTG; 382; DMP; 266; NELFINAVIR

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is an open label, AUC controlled study to determine the dosing regimen, safety and pharmacokinetics of liquid efavirenz in combination with nelfinavir in HIV-infected infants and children. Secondary objectives are to characterize the effect of this combination on antiviral activity, CD4/CD8 counts, duration of response and genotypic/phenotypic antiretroviral sensitivity of latent virus in PBMCs.

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。这是一项开放标签、AUC对照研究，旨在确定液体依非韦伦联合奈非那韦在hiv感染婴儿和儿童中的给药方案、安全性和药代动力学。次要目的是表征这种组合对pbmc中潜伏病毒的抗病毒活性、CD4/CD8计数、反应持续时间和基因型/表型抗逆转录病毒敏感性的影响。